THERADIAG overview

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has signed an partnership contract with ORGENTEC, a German company that is a leader on the global autoimmunity market, to provide it with quality control reagents called Alegria® Check. Medical analysis laboratories are having to comply with increasingly stringent regulatory requirements in terms of quality control. Theradiag has...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER) , a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained CE marking for four additional i-Tracker ® test kits for biotherapy monitoring. In 2020, Theradiag had already announced the market launch of its first four i-Tracker® test kits (i-Tracker® Infliximab, i-Tracker® Anti-Infliximab, i-Tracker® Adalimumab and i-Tracker® Anti-Adalimumab) designed for i-Track 10 ®...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2021. Events Dates* 2020 Full-Year Annual Revenue Monday February 1, 2021 2020 Full-Year Results Monday March 22, 2021 Annual General Meeting Thursday May 6, 2021 2021 First-Half Revenue Monday July 19, 2021 2021 First-Half Results Monday September 20,...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, announces the publication of a study that meets French National Authority for Health (HAS) requirements and highlights the quality of the antigenic tests it markets. The study, conducted by the virology laboratory of the Centre Hospitalier Universitaire d’Amiens from October 18 to November 27, compared the Certest antigen test distributed by Theradiag...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained a €1.9 million state-guaranteed loan ( Prêt Garanti par l’État or PGE) from a bank syndicate. The loan is 90% guaranteed by the French government, with an initial maturity of 12 months plus an extension option enabling Theradiag to defer repayment of the principal over a period of up to five years. Theradiag CEO...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan) , a company specializing in in vitro diagnostics and theranostics, has opened a new site in Tours, France. In July, Theradiag announced a partnership with the University of Tours: an exclusive licensing contract for making Covid-19 viral proteins, plus a global collaboration agreement. As part of this alliance, Theradiag wanted a local presence in France’s...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that its half-year financial report as at 30 June 2020 has been made available to the public and filed with the French regulator Autorité des Marchés Financiers (AMF). It is available in French only directly on THERADIAG's website, www.theradiag.com in the Investors / Financial News / Financial Reports section and on www.amf-france.org ....

Regulatory News: Theradiag (Paris:ALTER), a French company specializing in diagnostic tests for autoimmune and infectious diseases, today announces the market launch of a CE-marked antigen test for detecting COVID-19. On September 16, 2020 1 , an order dated September 15, 2020, amending the order of July 10, 2020 stipulating the general measures required to tackle the COVID-19 epidemic in regions emerging from the health state of emergency and those where it has been prolonged, was published in...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today presents its results for the six months ended June 30, 2020, as approved by the Board of Directors on September 17, 2020. 2020 H1 results €000 H1 2020 (Company statements) H1 2019 (1) (Company statements) H1 2019 (Reported conso. statements) Revenue 4,871 4,978 4,978 of which Theranostics 2,410 2,070 2,070 of which IVD 2,461 2,908 2,908 Operating...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan) , a company specializing in in vitro diagnostics and theranostics, is pleased to announce the launch of four new i-Tracker® assays designed to run on the automated IDS-iSYS analyser. These assays were developed by Theradiag to address the rapidly growing market of biologics drug monitoring. The four i-Tracker® assays: i-Tracker® Infliximab, i-Tracker®...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its consolidated half-year revenue and cash position at June 30, 2020, data that is currently being audited. Consolidated H1 2020 revenue of €4.9 million In thousands of euros June 30, 2020 June 30, 2019 Change Revenue* 4,871 4,976 -2.1% of which Theranostics 2,410 2,070 +16.5% of which LISA TRACKER® kits in routine use 2,410 2,041...

Regulatory News: The University of Tours and THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan) , a company specializing in in vitro diagnostics and theranostics, have just signed two agreements simultaneously. The first is an exclusive licensing agreement for the production and access to viral proteins initially synthesized by Prof. Antoine Touzé’s polyomavirus infections biology team (University of Tours MRU – INRAE...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, informs its shareholders that its Combined General Meeting was held on second call in closed session, without shareholders or other people allowed to assist being physically present, on Thursday 25 June 2020 at 2:00 pm at the Company's registered office and chaired by Mr. Pierre Morgon, Chairman of the Board of Directors. Following this Combined General...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today provides an update on its new Covid-19 test program launched in response to the global pandemic. To date, four tests have been approved by the National Reference Center in Paris (CNR): Two tests distributed by Theradiag (CE marked by their manufacturers): - One PCR test: Mikrogen - ampli Cube Coronavirus SARS-CoV-2 previously mentioned - Diagreat -...

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), specializes in in vitro diagnostics and theranostics. Regarding the new Covid-19 testing activity recently initiated, Theradiag confirms that the viremia test developed by Mikrogen, AmpliCube Coronavirus SARS-Cov-2 (RT-PCR on nasopharyngeal swab), has just been approved by the National Reference Center of Paris (CNR). Exclusive distribution of the latter, in France, will soon begin via Theradiag's usual commercial...